dr. mcdermott on immunotherapy-related aes in rcc
Published 7 years ago • 67 plays • Length 2:18Download video MP4
Download video MP3
Similar videos
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:23
dr. mcdermott discusses the future of immune checkpoints in rcc
-
1:50
nuances of immunotherapy-related aes in melanoma
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
0:45
dr. mcdermott on the role of vegf targeted therapy in rcc
-
1:27
dr. mcdermott on vegf/pd-1 inhibition in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
1:08
mcdermott: immunotherapy agents in renal cell carcinoma
-
1:29
dr. brahmer on managing immune-related aes in lung cancer
-
11:46
immune checkpoint inhibitors in renal cell carcinoma
-
0:42
dr. mcdermott on targeting pd-1 and pd-l1 in kidney cancer
-
1:16
mitigating immune-related aes in patients with autoimmune conditions
-
35:00
t cell checkpoint inhibitors in rcc: a new hope? david f. mcdermott, m.d.
-
3:32
multisystem immune-related aes with immunotherapy in nsclc
-
1:23
matthew burke on chemotherapy-related aes versus immunotherapy-related aes